Nitrogen Other Than As Nitro Or Nitroso Nonionically Bonded Patents (Class 514/561)
-
Patent number: 11666777Abstract: A photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient is disclosed herein. In one embodiment, a treatment laser is applied to a body portion of a patient using a painting technique, the treatment laser being configured to provide paint brush-type photodynamic therapy (PPDT) using the painting technique to the body portion of the patient by emitting light of a predetermined wavelength that is absorbed by tissue of the body portion of the patient to which a photosensitizer has been applied, the body portion of the patient being afflicted by a medical condition. The application of the treatment laser to the body portion of a patient using the painting technique treats the medical condition, reduces the symptoms associated with the medical condition, and/or alleviates the medical condition.Type: GrantFiled: November 29, 2020Date of Patent: June 6, 2023Inventor: Gholam A. Peyman
-
Patent number: 11660393Abstract: An implantable emergency management drug delivery system configured to deliver a medicament to reverse the effects of a drug overdose. The implantable emergency management drug delivery system including an implantable infusion pump configured to infuse a first medicament, and an emergency handling device having at least one physiological sensor configured to monitor a condition of a patient for a possibility of an overdose from the first medicament, a communication module configured to communicate the possibility of an overdose to the implantable infusion pump, and an implantable medicament delivery mechanism configured to deliver a second medicament to reduce one or more adverse physiological effects of the first medicament.Type: GrantFiled: April 24, 2020Date of Patent: May 30, 2023Assignee: Medtronic, Inc.Inventor: Touby A. Drew
-
Patent number: 11642312Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.Type: GrantFiled: April 30, 2021Date of Patent: May 9, 2023Assignee: MARENDA PHARMACEUTICALS LLCInventors: Andrew Favara, Marc Karetny
-
Patent number: 11642411Abstract: The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application or subcutaneous injection of said composition to an area of the skin of said patient, (b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and (c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizer as well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.Type: GrantFiled: August 23, 2018Date of Patent: May 9, 2023Assignee: BIOFRONTERA BIOSCIENCE GMBHInventor: Hermann Lübbert
-
Patent number: 11617731Abstract: This disclosure provides pharmaceutical compositions comprising defined amino acid components, and methods for treating traumatic brain injury comprising administering an effective amount of the compositions to a subject in need thereof.Type: GrantFiled: April 27, 2018Date of Patent: April 4, 2023Assignee: AXCELLA HEALTH, INC.Inventors: Sean Carroll, Raffi Afeyan, Gianluca De Rienzo, Matthew Russell
-
Patent number: 11607380Abstract: A method for treating skin of a person is disclosed. The method can include topically applying to the skin of the person a composition comprising an effective amount of an aqueous, alcoholic, or aqueous-alcoholic extract from Vinca major, wherein the composition reduces melanin production in the skin, increases antioxidant activity in the skin, and/or increases skin moisture content.Type: GrantFiled: March 5, 2021Date of Patent: March 21, 2023Assignee: MARY KAY INC.Inventors: Tiffany Florence, David Gan, Michelle Hines
-
Patent number: 11602517Abstract: The present invention relates to a composite agent comprising polmacoxib and pregabalin. The present invention relates to a pharmaceutical composition and a drug or pain reliever, which each comprise the two active ingredients of polmacoxib and pregabalin and, more particularly, to a drug or pain reliever for treatment of moderately severe, acute, chronic, or neuropathic pain attributed to inflammation and various factors, an effect thereof, and a use thereof.Type: GrantFiled: March 20, 2019Date of Patent: March 14, 2023Assignee: CrystalGenomics, Inc.Inventors: Jae Pyoung Cho, Joong Myung Cho
-
Patent number: 11590105Abstract: Methods of treatment, pharmaceutically acceptable solutions, and implantable devices are provided for the intrathecal treatment of AED-resistant seizures using levetiracetam.Type: GrantFiled: August 12, 2020Date of Patent: February 28, 2023Assignee: Sintetica S.A.Inventors: Augusto Mitidieri, Elisabetta Donati, Clara Bianchi, Barbara Piccagli
-
Patent number: 11576926Abstract: A synergistic composition of naturally occurring active ingredients is described, which has proved particularly effective in the treatment and/or prevention of epistaxis, particularly in acute or chronic episodes of infectious and inflammatory epistaxis. The composition includes the synergistic combination of hyaluronic acid or a salt thereof, silver, vitamin B5 or pro-vitamin B5, and optionally vitamin E or an ester thereof.Type: GrantFiled: September 11, 2019Date of Patent: February 14, 2023Assignee: NEILOS S.R.L.Inventor: Umberto Di Maio
-
Patent number: 11576885Abstract: Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury.Type: GrantFiled: October 6, 2020Date of Patent: February 14, 2023Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIAInventor: Akiva S. Cohen
-
Patent number: 11576911Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.Type: GrantFiled: March 9, 2020Date of Patent: February 14, 2023Assignee: GLYTECH LLCInventor: Daniel C. Javitt
-
Patent number: 11541065Abstract: A method for treating a hyperhomocysteinemic subject having cerebral ischemic stroke generally includes administering to the hyperhomocysteinemic subject, following cerebral stroke, a composition that includes an inhibitor or an antagonist of a GluN2A-containing N-methyl-D-aspartate receptor (NMDAR) in an amount effective to ameliorate at least one symptom or clinical sign of cerebral stroke.Type: GrantFiled: July 8, 2019Date of Patent: January 3, 2023Inventors: Ranjana Poddar, Surojit Paul
-
Patent number: 11491127Abstract: A compound having the formula (I) R1-COOH. R1 is an alkyl or alkenyl group having a C7-11 backbone, optionally branched with a C1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof. The backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the ? carbon of R1, or of only single methyl groups at both the ? and ?-1 carbons of R1, and provided that when R1 is an alkyl group having a C8 or C11 backbone, the branching does not consist only of a propyl group at the a carbon of R1.Type: GrantFiled: December 20, 2019Date of Patent: November 8, 2022Assignee: UCL BUSINESS PLCInventors: Robin Simon Brooke Williams, Matthew Walker
-
Patent number: 11478473Abstract: The present invention provides a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I): wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.Type: GrantFiled: April 3, 2020Date of Patent: October 25, 2022Assignees: Amino Up Co., Ltd., Otsuka Pharmaceutical Co., Ltd.Inventors: Kazunori Goto, Jun Nakahigashi, Atsuya Sato, Yosuke Hirayama, Moeri Horikoshi, Noriyuki Kouda, Syoichiro Inoue, Ikutaro Sato, Manami Kato
-
Patent number: 11475983Abstract: HIPAA-compliant computer security method and system for recording, using a video camera, electronic visual personal health information of at least two individuals, including an individual under care, and preventing unauthorized access of the user to the video information. The video is compared to physical attribute information of the individuals stored in the computer system's memory, and the individuals are identified by facial matching. The user's stored caseload has authorization profile information including access to individuals under care. The identified individuals are compared to the user's caseload information, and the user is granted access to part of the video of the individual under care, the video of the other individuals is blurred, and the resulting video is transmitted to the user's caseload for viewing. The video information is compared to stored historical information to determine an indicated negative outcome, and transmit a signal for initiating preventative action.Type: GrantFiled: November 26, 2019Date of Patent: October 18, 2022Assignee: Therap Services, LLCInventors: Richard Allen Robbins, Justin Mark Brockie, James Michael Kelly, Asif Ali, Mojahedul Hoque Abul Hasanat, Omar Faruq, Sazzad Rafique, Tahseen Mohammad, Ummy Habiba, Suraiya Parveen, Jeremy Ian Schulman Robbins
-
Patent number: 11426376Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.Type: GrantFiled: September 21, 2021Date of Patent: August 30, 2022Assignee: SynAgile CorporationInventors: Adam Heller, Ephraim Heller, John Spiridigliozzi, Steven Diianni, Karl Göran Westerberg
-
Patent number: 11407812Abstract: Certain embodiments of the invention provide a method of treating an excitable cell-related disease or condition in a mammal in need thereof, comprising administering to the mammal an effective amount of a vector comprising an expression cassette, wherein the expression cassette comprises a promoter operably linked to a nucleic acid encoding a subunit of a multimeric ion channel.Type: GrantFiled: September 28, 2016Date of Patent: August 9, 2022Assignee: GOLEINI INC.Inventors: Griffith Roger Thomas, Shawnalea Jimee Frazier
-
Patent number: 11395843Abstract: A composition for increasing dermal nitric oxide comprises in combination, a quantity of beet root extract, a quantity of aloe vera extract, a quantity of willow bark extract and a quantity of curcumin powder suspended in a base suitable for application to the skin of a user. The composition may be formed by providing the base suitable for application to the skin of a user and suspending within the base, in combination, a quantity of beet root extract, a quantity of aloe vera extract, a quantity of willow bark extract and a quantity of curcumin powder.Type: GrantFiled: November 1, 2019Date of Patent: July 26, 2022Assignee: Spinal Relief Centres of CanadaInventor: Cary Chousky
-
Patent number: 11345654Abstract: The present invention relates to compounds and methods useful for selectively modulating mTORC1 activity.Type: GrantFiled: October 24, 2019Date of Patent: May 31, 2022Assignee: NAVITOR PHARMACEUTICALS, INC.Inventor: Silvia Lenzini
-
Patent number: 11278502Abstract: The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.Type: GrantFiled: September 28, 2018Date of Patent: March 22, 2022Assignee: LUPIN LIMITEDInventors: Shirishkumar Kulkarni, Satish Kumar Dalal, Harshal Jahagirdar, Kishore Kumar Konda
-
Patent number: 11273138Abstract: The present invention encompasses an amino acid composition for stimulating muscle protein synthesis. Further, the present disclosure relates generally to the use of an anabolic amino acid composition for the stimulation of muscle protein synthesis. In particular, disclosed are compositions and methods of using the same for the prevention and/or treatment of a loss of any one of muscle mass, muscle strength, muscle function, and physical function, or any combination thereof, in a mammal, especially an adult mammal. Also provided are kits comprising a composition for the stimulation of muscle protein synthesis and, in certain embodiments, instructions for administration.Type: GrantFiled: November 2, 2018Date of Patent: March 15, 2022Assignee: BioVentures, LLCInventors: Robert R. Wolfe, Arny Ferrando
-
Patent number: 11225457Abstract: The present invention is related to a process for preparing safinamide and salts thereof, preferably safinamide methanesulfonate, with high yields and high enantiomeric and chemical purity without the need of using highly pure intermediates. The process of the present invention is suitable for the production of safinamide and its salts, preferably safinamide methanesulfonate, at industrial scale.Type: GrantFiled: August 5, 2020Date of Patent: January 18, 2022Assignee: MEDICHEM, S.A.Inventors: Yisong Wen, David Font Gimbernat, Ernesto Durán López
-
Patent number: 11224581Abstract: An object of the present invention is to provide a novel composition for promoting ketone body production. The present invention provides a composition for use in promoting ketone body production, comprising one or more amino acid(s) selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid. The composition according to the present invention may further comprise either or both of a medium-chain fatty acid and a medium-chain fatty acid ester.Type: GrantFiled: August 18, 2017Date of Patent: January 18, 2022Inventors: Kentaro Nakamura, Kinya Ashida, Akina Sasayama, Yuri Saito
-
Patent number: 11213495Abstract: The present invention relates to a method for decreasing the psychotomimetic side effects and enhancing the antidepressant-like effects of ketamine by the combination of ketamine with a methylglycine derivative. The present invention also relates to a method for depression treatment comprising administrating ketamine combined with a methylglycine derivative. The present invention further provides a method for preventing or treating addictive disorders of ketamine by administrating a methylglycine derivative.Type: GrantFiled: May 25, 2017Date of Patent: January 4, 2022Assignee: NATIONAL HEALTH RESEARCH INSTITUTESInventor: Hwei-Hsien Chen
-
Patent number: 11203596Abstract: Disclosed are compound and methods of using the compounds for modulating ornithine aminotransferase (OAT) activity. The disclosed compound are characterized as analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid which may be formulated as therapeutic agents for treating diseases and disorders associated with ornithine aminotransferase (OAT) activity such as hepatocellular carcinoma and other cancers.Type: GrantFiled: February 25, 2020Date of Patent: December 21, 2021Assignee: Northwestern UniversityInventors: Richard B. Silverman, Matthew J. Moschitto
-
Patent number: 11147785Abstract: A composition and methods of administration are provides utilizing Monosodium L-Glutamate Monohydrate in a stabilized form at an alkaline pH.Type: GrantFiled: March 23, 2021Date of Patent: October 19, 2021Inventors: Jack Mentkow, Lisa Mentkow
-
Patent number: 11147780Abstract: Disclosed herein is a multidrug pain management package to dispense two or more medicaments to treat pain comprising a primary n-polygon, and one or more concentric m-polygons, wherein each side of the n-polygon and m-polygons have at least n or m-medicament chambers capable of holding the two or more medicaments. Also disclosed herein is a multidrug pain management package comprising a disk, wherein the disk is divided into equally spaced regions, and wherein each region has chambers capable of holding medicaments. Also disclosed herein are single formulations to treat pain.Type: GrantFiled: June 11, 2020Date of Patent: October 19, 2021Assignee: ALGIA PHARMA, LLCInventors: David L. Steinberg, Joseph Loskove, Hannah Thompson
-
Patent number: 11147926Abstract: According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.Type: GrantFiled: February 3, 2016Date of Patent: October 19, 2021Assignee: PIRAMAL CRITICAL CARE, INC.Inventors: John J. Foster, Thomas R. Prentice
-
Patent number: 11135191Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.Type: GrantFiled: September 24, 2020Date of Patent: October 5, 2021Assignee: SynAgile CorporationInventors: Adam Heller, Ephraim Heller, John Spiridigliozzi, Steven Diianni, Evangelos C. Eleftheriou
-
Patent number: 11123320Abstract: Various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.Type: GrantFiled: May 21, 2018Date of Patent: September 21, 2021Assignees: SBI PHARMACEUTICALS, CO., LTD., NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITYInventors: Tohru Tanaka, Kiwamu Takahashi, Keiji Inoue, Motoaki Saito, Masayuki Tsuda, Hideo Fukuhara, Takahira Kuno, Shogo Shimizu
-
Patent number: 11103483Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.Type: GrantFiled: July 12, 2019Date of Patent: August 31, 2021Assignee: Eagle Pharmaceuticals, Inc.Inventors: Nagesh R. Palepu, Philip Christopher Buxton
-
Patent number: 11078153Abstract: Disclosed are enantiomerically pure cyclopentane-based compounds that are prepared by a multiple-step synthesis process. The disclosed compounds have been designed to inhibit gamma-aminobutyric acid-amino transferase (GABA-AT) activity and ornithine aminotransferase (OAT) activity. Some of the enantiomerically pure compounds inhibit OAT activity more potently than the racemic compound. The disclosed compounds may be used to selectively inhibit OAT activity, for example, to treat hepatocellular carcinoma and/or used to selected inhibit GABA-AT activity, for example, to treat neurological diseases and disorders.Type: GrantFiled: April 3, 2020Date of Patent: August 3, 2021Assignee: Northwestern UniversityInventor: Richard B. Silverman
-
Patent number: 10973793Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.Type: GrantFiled: February 7, 2020Date of Patent: April 13, 2021Assignee: AXCELLA HEALTH INC.Inventors: William Comb, Michael Hamill, Raffi Afeyan
-
Patent number: 10952973Abstract: Provided are a production method of a pregabalin-containing composition, which suppresses crystallization of pregabalin, and a pregabalin-containing composition that shows suppressed crystallization of Pregabalin. The production method of the pregabalin-containing composition of the present invention contains steps of: (1) dissolving pregabalin in an aqueous solution of an acid to prepare an aqueous solution of a salt of pregabalin; (2) mixing the aqueous solution of pregabalin salt and a hydrophilic resin to prepare a mixture thereof; and (3) concentrating the mixture; wherein the acid has an acid dissociation constant lower than that of pregabalin.Type: GrantFiled: March 15, 2019Date of Patent: March 23, 2021Assignee: NITTO DENKO CORPORATIONInventors: Tomohito Takita, Kaiji Fujiwara, Chie Matsumoto, Akinori Sugiyama, Jyun Isayama, Toshinari Honda, Ai Funasaki
-
Patent number: 10934318Abstract: The subject invention provides methods and procedures for synthesis and/or semi-synthesis of the novel antibiotic arsinothricin (AST) and derivatives. Arsinothricin (AST), a new broad-spectrum organoarsenical antibiotic, is a non-proteinogenic analog of glutamate that effectively inhibits glutamine synthetase. The subject invention provides chemical synthesis of an intermediate in the pathway of AST synthesis, hydroxyarsinothricin (AST-OH), which can be converted to AST by enzymatic methylation catalyzed by the ArsM As(III) S-adenosylmethionine methyltransferase. The methods provide a source of the novel antibiotic that will be required for future clinical trials. The subject invention also provides AST derivatives as a new class of antibiotics.Type: GrantFiled: June 5, 2020Date of Patent: March 2, 2021Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: Barry P. Rosen, Stanislaw F. Wnuk, Masafumi Yoshinaga, Md Abu Hasan Howlader, Sk Md Sazzad Hossain Suzol
-
Patent number: 10905670Abstract: The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.Type: GrantFiled: April 19, 2017Date of Patent: February 2, 2021Assignee: INTRABIO LTD.Inventors: Mallory Factor, Michael Strupp
-
Method and composition for increasing muscle protein synthesis and/or functional strength in mammals
Patent number: 10888571Abstract: A method and composition for preserving muscle mass and function by increasing muscle protein synthesis and/or decreasing muscle protein degradation in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at least two of an essential amino acid, an amino acid derivative, and a nitrogenous organic acid. In a particular embodiment, the protein building composition comprises leucine, L-carnitine, and creatine. The protein building composition can decrease TNF-? and increase mTOR expression in muscle.Type: GrantFiled: December 16, 2016Date of Patent: January 12, 2021Assignee: Lonza Consumer Health Inc.Inventors: Aouatef Bellamine, Ilya Zhivkovich, Ulla Freitas -
Patent number: 10874626Abstract: Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid pain drug in an aqueous carrier. The pharmaceutical formulation can have a pH of about 2.0 to about 10.0. The at least one non-opioid pain drug can be acetaminophen. The components can be included in any amount suitable for purposes of obtaining properties desirable for an injectable infusion, for example an intravenous infusion.Type: GrantFiled: April 7, 2017Date of Patent: December 29, 2020Assignee: Nevakar Inc.Inventors: Varun Khurana, Vivek Yadav, Jack Martin Lipman, Tao Zhang, Iouri V. Ilitchev, Tushar Hingorani, Kumaresh Soppimath, Navneet Puri
-
Patent number: 10870681Abstract: The present invention provides method treating a subject suffering from a clinical condition associated with CXCR4 activity, said method comprising administering to a subject in need of such a treatment a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof, wherein a is 0 or 1; AA1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, or optionally substituted homocysteine; AA2 along with the sulfur atom that is attached thereto is cysteine or homocysteine; Ar1 is an optionally substituted aryl; X1 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), or Lys(iPr); X2 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), Lys(iPr), a D-isomer thereof, or absent; X3 is Gly or absent; X4 is Phe, 2Nal, 1Nal, or absent; X5 is Gly or absent; R2 is —OR4 or —NHR5; R4 is H or alkyl; and R5 is H, alkyl, optionally substituted aryl, optionally substituted aralkyl.Type: GrantFiled: June 4, 2019Date of Patent: December 22, 2020Assignee: MAINLINE BIOSCIENCES LLCInventors: Junge Zhang, Liang Zeng Yan
-
Patent number: 10786474Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.Type: GrantFiled: March 13, 2020Date of Patent: September 29, 2020Assignee: SynAgile CorporationInventors: Adam Heller, John Spiridigliozzi
-
Patent number: 10765651Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.Type: GrantFiled: May 15, 2019Date of Patent: September 8, 2020Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
-
Patent number: 10716855Abstract: A pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin is described.Type: GrantFiled: December 5, 2014Date of Patent: July 21, 2020Assignee: GALDERMA RESEARCH & DEVELOPMENTInventors: Hans Christian Wulf, Gloria Sanclemente
-
Patent number: 10695310Abstract: Methods of treatment using D-serine to target brain cells expressing GluN3 subunit-containing triheteromeric NMDARs are disclosed. The methods include inhibiting calcium ion uptake by brain cells, treating epilepsy, and treating seizures by artificially administering D-serine.Type: GrantFiled: February 25, 2019Date of Patent: June 30, 2020Assignee: Florida State University Research Foundation, Inc.Inventor: Sanjay S. Kumar
-
Patent number: 10660887Abstract: Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.Type: GrantFiled: July 16, 2017Date of Patent: May 26, 2020Assignee: GLYTECH, LLCInventor: Daniel C. Javitt
-
Patent number: 10654794Abstract: Disclosed are a fused tricyclic ?-amino acid derivative and a medical use thereof, in particular, the present invention relates to a fused cyclic ?-amino acid derivative as shown in general formula (I), or a stereoisomer, solvate, metabolite, prodrug, pharmaceutically acceptable salt or eutectic thereof, a pharmaceutical composition containing same, and the use of a compound or the composition in the field of analgesia, wherein the definitions of each substituent in general formula (I) are the same as the definitions in the description.Type: GrantFiled: September 12, 2017Date of Patent: May 19, 2020Assignee: SICHUAN HAISO PHARMACEUTICAL CO., LTD.Inventors: Yao Li, Zongjun Shi, Bo Xu
-
Patent number: 10646435Abstract: The present invention provides pasty or liquid compositions for applications on mucous membranes of cavities easily reached by hand, having a bio-adhesive prolonged effect or release. The composition includes a polysaccharide matrix agent selected from the group constituting of lambda carrageenan and iota carrageenan. The matrix allows the in situ formation of a matrix film with a reinforced bio-adhesive capacity due to complexation reactions between the polysaccharide matrix agent and the components of the local secretions of the mucous membranes. The compositions can also include a lecithin compound as a reinforcing agent of the intrinsic bio-adhesive properties of the polysaccharide matrix agent. The composition can further include at least one of (a) a hydration medium for the polysaccharide matrix agent, (b) a lecithin co-solvent allowing the dispersion of the micellar lecithin solution in the hydration medium, (c) an additive or additives, and (d) at least one active ingredient.Type: GrantFiled: April 22, 2016Date of Patent: May 12, 2020Assignee: CARE & PHARMA PERSPECTIVES SAInventor: Laurence Paris
-
Patent number: 10596136Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.Type: GrantFiled: June 19, 2019Date of Patent: March 24, 2020Assignee: AXCELLA HEALTH INC.Inventors: Manu Chakravarthy, William Comb, Michael Hamill, Tony Tramontin
-
Patent number: 10588882Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.Type: GrantFiled: June 10, 2019Date of Patent: March 17, 2020Assignee: SynAgile CorporationInventors: Adam Heller, John Spiridigliozzi
-
Patent number: 10583138Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.Type: GrantFiled: May 24, 2018Date of Patent: March 10, 2020Assignee: GLYTECH, LLCInventor: Daniel C. Javitt
-
Patent number: 10485776Abstract: A medicament to be applied as an external preparation for therapeutic treatment of a local symptom of a neuropathic disease, which contains gabapentin or pregabalin in the form of an aqueous solution.Type: GrantFiled: May 23, 2018Date of Patent: November 26, 2019Assignee: KEMPHYS LTD.Inventors: Koichi Shudo, Kiyoshi Sugiyama